Centene Corporation (NYSE:CNC) Shows Stabilizing Momentum Despite Margin Pressure

Centene presents mixed signals: operational reach and cash-generation metrics support a valuation gap, while compressed margins and recent technicals suggest cautious near-term price action.

Recent News

In early November 2025 Centene announced expanded Medicare Advantage and Marketplace plan offerings across multiple states and additional state contract awards, increasing program availability for 2026. On January 6, 2026 market commentary noted a 16.3% three-month share gain and described early stabilization after 2025 cost pressures.

Technical Analysis

Trend strength (ADX/DI): ADX at 19.69 indicates no established trend; DI+ at 29.63 shows a decreasing trend, which reads as bearish pressure relative to prior strength; DI- at 20.33 shows a dip-and-reversal pattern, interpreted here as bearish since DI- has moved higher from its prior dip.

MACD and momentum: MACD sits at 1.60 below the signal line at 1.71 and shows a decreasing trend, a bearish momentum profile given the negative and declining MACD relationship to its signal.

Price vs moving averages and bands: Last close $46.28 trades above the 200-day average of $41.63 and above the 50-day average of $40.93; the 12-day EMA sits at $45.52 and shows an increasing trend, supporting short-term upside bias, while the 20-day average near $46.09 and the Bollinger upper band around $46.72 frame immediate resistance and range limits. The super-trend lower support lies near $44.05.

MRO (Momentum/Regression Oscillator): MRO at -6.06 with a dip-and-reversal description indicates the price sits below WMDST’s target and implies potential upside pressure as the market works toward fair-value alignment.

RSI: RSI at 62.58 with a dip-and-reversal pattern signals regained bullish momentum without overbought extremes, consistent with a near-term rebound bias if momentum holds above mid-60s.

 


Fundamental Analysis

  • Profitability: Net income for the period shows a loss of $6,631,000,000 and EBIT registers negative $6,504,000,000; EBIT margin stands at -13.09%, which sits above the industry peer low of -14.17% but remains below the industry peer mean of 5.33% and median of 3.47%.
  • Revenue and growth rates: Total revenue equals $49,690,000,000 with trailing revenue growth of 1.95%; quarter-over-quarter revenue growth reads -57.27% and year-over-year revenue growth reads -64.57% (reported values), indicating volatile period-to-period comparisons that contrast with the modest trailing growth figure.
  • Earnings per share and outlook metrics: Reported EPS actual $0.50 versus estimate -$0.16 produced an EPS surprise of $0.66, equal to a 412.5% surprise ratio. Forward EPS sits at $0.7475 with a forward P/E of 19.46, while the trailing P/E records 70.03; the divergence implies market expectations of improving earnings versus the most-recent trailing outcome.
  • Cash generation and valuation signals: Free cash flow totaled $1,145,000,000 with a free cash flow yield of 6.65%, which stands above the industry peer mean free cash flow yield of 2.18%; cash and short-term investments total $19,237,000,000 supporting liquidity with a cash ratio near 0.47 and current ratio about 1.08.
  • Balance sheet and leverage: Total debt $17,583,000,000 produces debt-to-assets of 21.42%, below the industry peer mean of 34.63%; debt-to-equity sits at 0.839, slightly above the industry peer median of 0.814. Interest expense remains modest at $170,000,000, but interest coverage reads negative given recent losses.
  • Operational efficiency: Asset turnover at 0.5899 sits above the industry peer mean of 0.3917, suggesting relatively stronger revenue generation per asset base despite compressed margins; operating margin sits at -0.425% versus an industry peer mean of 7.381%.
  • Valuation conclusion: The current valuation as determined by WMDST registers as under-valued, supported by a low price-to-book of 0.82 (below the industry peer mean of 2.20 and median of 1.72), an enterprise-value-to-revenue metric near 0.313, and a free cash flow yield above peer mean, while elevated trailing P/E and negative profitability metrics explain the discount.
MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-09-30
REPORT DATE: 2025-10-29
NEXT REPORT DATE: 2026-01-28
CASH FLOW  Begin Period Cash Flow 14.6 B
 Operating Cash Flow 1.4 B
 Capital Expenditures -211.00 M
 Change In Working Capital 763.0 M
 Dividends Paid
 Cash Flow Delta 2.6 B
 End Period Cash Flow 17.2 B
 
INCOME STATEMENT REVENUE
 Total Revenue 49.7 B
 Forward Revenue -688.16 M
COSTS
 Cost Of Revenue 46.4 B
 Depreciation 147.0 M
 Depreciation and Amortization 317.0 M
 Research and Development
 Total Operating Expenses 49.9 B
PROFITABILITY
 Gross Profit 3.3 B
 EBITDA -6.19 B
 EBIT -6.50 B
 Operating Income -211.00 M
 Interest Income
 Interest Expense 170.0 M
 Net Interest Income -170.00 M
 Income Before Tax -6.67 B
 Tax Provision -42.00 M
 Tax Rate 0.629 %
 Net Income -6.63 B
 Net Income From Continuing Operations -6.63 B
EARNINGS
 EPS Estimate -0.16
 EPS Actual 0.50
 EPS Difference 0.66
 EPS Surprise 412.5 %
 Forward EPS 0.75
 
BALANCE SHEET ASSETS
 Total Assets 82.1 B
 Intangible Assets 15.7 B
 Net Tangible Assets 5.3 B
 Total Current Assets 44.1 B
 Cash and Short-Term Investments 19.2 B
 Cash 17.1 B
 Net Receivables 23.1 B
 Inventory
 Long-Term Investments 2.0 B
LIABILITIES
 Accounts Payable 16.9 B
 Short-Term Debt 38.0 M
 Total Current Liabilities 40.6 B
 Net Debt 525.0 M
 Total Debt 17.6 B
 Total Liabilities 61.0 B
EQUITY
 Total Equity 20.9 B
 Retained Earnings 9.8 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 42.63
 Shares Outstanding 491.414 M
 Revenue Per-Share 101.12
VALUATION
 Market Capitalization 17.2 B
 Enterprise Value 15.6 B
 Enterprise Multiple -2.514
Enterprise Multiple QoQ -103.21 %
Enterprise Multiple YoY -118.73 %
Enterprise Multiple IPRWA high: 190.244
median: 35.913
mean: 12.901
CNC: -2.514
low: -105.843
 EV/R 0.313
CAPITAL STRUCTURE
 Asset To Equity 3.919
 Asset To Liability 1.345
 Debt To Capital 0.456
 Debt To Assets 0.214
Debt To Assets QoQ 5.284 %
Debt To Assets YoY 15766.667 %
Debt To Assets IPRWA high: 0.914
mean: 0.346
median: 0.262
CNC: 0.214
low: 0.005
 Debt To Equity 0.839
Debt To Equity QoQ 30.872 %
Debt To Equity YoY 20573.892 %
Debt To Equity IPRWA high: 3.285
CNC: 0.839
median: 0.814
mean: -0.268
low: -7.485
PRICE-BASED VALUATION
 Price To Book (P/B) 0.821
Price To Book QoQ 28.208 %
Price To Book YoY -38.348 %
Price To Book IPRWA high: 11.321
mean: 2.199
median: 1.722
CNC: 0.821
low: -1.461
 Price To Earnings (P/E) 70.028
Price To Earnings QoQ -176.556 %
Price To Earnings YoY 59.054 %
Price To Earnings IPRWA high: 167.73
CNC: 70.028
mean: 60.79
median: 54.99
low: -41.31
 PE/G Ratio -0.17
 Price To Sales (P/S) 0.346
Price To Sales QoQ -3.873 %
Price To Sales YoY -60.002 %
Price To Sales IPRWA high: 19.515
mean: 2.797
median: 1.147
CNC: 0.346
low: 0.079
FORWARD MULTIPLES
Forward P/E 19.463
Forward PE/G -0.047
Forward P/S -10.619
EFFICIENCY OPERATIONAL
 Operating Leverage 3792.345
ASSET & SALES
 Asset Turnover Ratio 0.59
Asset Turnover Ratio QoQ 4.944 %
Asset Turnover Ratio YoY 16.144 %
Asset Turnover Ratio IPRWA high: 0.945
CNC: 0.59
median: 0.401
mean: 0.392
low: 0.029
 Receivables Turnover 2.225
Receivables Turnover Ratio QoQ 0.409 %
Receivables Turnover Ratio YoY -7.683 %
Receivables Turnover Ratio IPRWA high: 9.084
mean: 3.804
median: 3.655
CNC: 2.225
low: 0.147
 Inventory Turnover
Inventory Turnover Ratio QoQ
Inventory Turnover Ratio YoY
Inventory Turnover Ratio IPRWA
 Days Sales Outstanding (DSO) 41.007
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 10.725
Cash Conversion Cycle Days QoQ
Cash Conversion Cycle Days YoY
Cash Conversion Cycle Days IPRWA high: 99.303
median: 15.133
mean: 10.834
CNC: 10.725
low: -55.902
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 14.478
 CapEx To Revenue -0.004
 CapEx To Depreciation -1.435
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 38.5 B
 Net Invested Capital 38.5 B
 Invested Capital 38.5 B
 Net Tangible Assets 5.3 B
 Net Working Capital 3.4 B
LIQUIDITY
 Cash Ratio 0.473
 Current Ratio 1.084
Current Ratio QoQ -1.227 %
Current Ratio YoY -1.258 %
Current Ratio IPRWA high: 3.196
CNC: 1.084
mean: 1.066
median: 0.88
low: 0.023
 Quick Ratio
Quick Ratio QoQ
Quick Ratio YoY
Quick Ratio IPRWA
COVERAGE & LEVERAGE
 Debt To EBITDA -2.842
 Cost Of Debt 0.961 %
 Interest Coverage Ratio -38.259
Interest Coverage Ratio QoQ 7375.93 %
Interest Coverage Ratio YoY -713.816 %
Interest Coverage Ratio IPRWA high: 30.491
mean: 6.456
median: 5.31
low: -11.697
CNC: -38.259
 Operating Cash Flow Ratio -0.111
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 30.282
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate -4.986 %
 Revenue Growth 1.945 %
Revenue Growth QoQ -57.272 %
Revenue Growth YoY -64.572 %
Revenue Growth IPRWA high: 14.194 %
median: 3.999 %
mean: 3.327 %
CNC: 1.945 %
low: -8.694 %
 Earnings Growth -412.5 %
Earnings Growth QoQ 250.807 %
Earnings Growth YoY 1147.807 %
Earnings Growth IPRWA high: 131.373 %
median: 1.754 %
mean: -7.05 %
low: -66.667 %
CNC: -412.5 %
MARGINS
 Gross Margin 6.543 %
Gross Margin QoQ 8.22 %
Gross Margin YoY -31.858 %
Gross Margin IPRWA high: 96.429 %
mean: 29.098 %
median: 14.673 %
CNC: 6.543 %
low: -4.713 %
 EBIT Margin -13.089 %
EBIT Margin QoQ 7253.371 %
EBIT Margin YoY -601.494 %
EBIT Margin IPRWA high: 19.623 %
mean: 5.327 %
median: 3.465 %
CNC: -13.089 %
low: -14.17 %
 Return On Sales (ROS) -0.425 %
Return On Sales QoQ -48.609 %
Return On Sales YoY -116.284 %
Return On Sales IPRWA high: 16.487 %
mean: 7.381 %
median: 2.448 %
CNC: -0.425 %
low: -12.809 %
CASH FLOW
 Free Cash Flow (FCF) 1.1 B
 Free Cash Flow Yield 6.654 %
Free Cash Flow Yield QoQ -25.919 %
Free Cash Flow Yield YoY -314.024 %
Free Cash Flow Yield IPRWA high: 14.006 %
CNC: 6.654 %
median: 2.383 %
mean: 2.181 %
low: -12.138 %
 Free Cash Growth -27.394 %
Free Cash Growth QoQ -286.468 %
Free Cash Growth YoY -82.536 %
Free Cash Growth IPRWA high: 316.092 %
CNC: -27.394 %
median: -66.858 %
mean: -110.735 %
low: -300.903 %
 Free Cash To Net Income -0.173
 Cash Flow Margin -9.088 %
 Cash Flow To Earnings 0.681
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) -7.871 %
Return On Assets QoQ 2595.548 %
Return On Assets YoY -1013.109 %
Return On Assets IPRWA high: 6.141 %
median: 1.207 %
mean: 0.985 %
CNC: -7.871 %
low: -14.166 %
 Return On Capital Employed (ROCE) -15.689 %
 Return On Equity (ROE) -0.317
Return On Equity QoQ 3329.577 %
Return On Equity YoY -1312.371 %
Return On Equity IPRWA high: 0.237
median: 0.019
mean: -0.051
CNC: -0.317
low: -0.36
 DuPont ROE -27.428 %
 Return On Invested Capital (ROIC) -16.774 %
Return On Invested Capital QoQ 10863.399 %
Return On Invested Capital YoY 246.213 %
Return On Invested Capital IPRWA high: 7.692 %
median: 2.996 %
mean: 2.399 %
low: -1.536 %
CNC: -16.774 %

Six-Week Outlook

Near-term price action should hinge on momentum indicators and earnings-related news flow. Technicals present a mixed message: MACD below its signal and a decreasing DI+ point to short-term downside risk, while price trading above the 50‑ and 200‑day averages and a negative MRO imply potential reversion toward fair value. Watch volume and whether the 12-day EMA (around $45.52) maintains its upward slope and whether RSI sustains readings above 60; if those conditions hold the stock may attempt further consolidation near the 20‑day band, whereas renewed MACD deterioration or a fall below the super-trend lower at $44.05 would favor pressure back toward the mid‑$40s support area. No trading entry or exit recommendations appear in this outlook.

About Centene Corporation

Centene Corporation (NYSE:CNC) delivers comprehensive healthcare services, primarily targeting under-insured and uninsured populations across the United States. Established in 1984 and based in St. Louis, Missouri, Centene develops a wide array of health plans through its Medicaid, Medicare, and Commercial segments. The Medicaid segment offers expanded health plans, children’s health insurance programs, and long-term services. In the Medicare segment, Centene addresses the needs of seniors with special needs plans, Medicare supplements, and prescription drug plans. The Commercial segment provides marketplace insurance products for individuals and businesses, ensuring extensive access to healthcare services. Centene actively participates in government healthcare contracts, including the TRICARE program for military families, highlighting its dedication to diverse communities. The company also manages clinical healthcare services, pharmacies, and provides dental and speech therapy, promoting a holistic healthcare approach. By collaborating with primary and specialty care physicians, hospitals, and ancillary providers, Centene aims to deliver personalized, high-quality care to millions of Americans, emphasizing innovation and community well-being.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.